GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (STU:RB0) » Definitions » Cyclically Adjusted PS Ratio

Regenxbio (STU:RB0) Cyclically Adjusted PS Ratio : 2.42 (As of Jun. 02, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Regenxbio Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Regenxbio's current share price is €7.85. Regenxbio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €3.25. Regenxbio's Cyclically Adjusted PS Ratio for today is 2.42.

The historical rank and industry rank for Regenxbio's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:RB0' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.67   Med: 2.96   Max: 5.92
Current: 2.51

During the past years, Regenxbio's highest Cyclically Adjusted PS Ratio was 5.92. The lowest was 1.67. And the median was 2.96.

STU:RB0's Cyclically Adjusted PS Ratio is ranked better than
69.15% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs STU:RB0: 2.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Regenxbio's adjusted revenue per share data for the three months ended in Mar. 2025 was €1.601. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.25 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenxbio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Regenxbio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Cyclically Adjusted PS Ratio Chart

Regenxbio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.34

Regenxbio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.50 3.63 3.20 2.34 2.03

Competitive Comparison of Regenxbio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Regenxbio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Regenxbio's Cyclically Adjusted PS Ratio falls into.


;
;

Regenxbio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Regenxbio's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=7.85/3.25
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenxbio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Regenxbio's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.601/134.9266*134.9266
=1.601

Current CPI (Mar. 2025) = 134.9266.

Regenxbio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.049 100.684 0.066
201509 0.211 100.392 0.284
201512 0.155 99.792 0.210
201603 0.013 100.470 0.017
201606 0.080 101.688 0.106
201609 0.004 101.861 0.005
201612 0.061 101.863 0.081
201703 0.016 102.862 0.021
201706 0.190 103.349 0.248
201709 0.036 104.136 0.047
201712 0.055 104.011 0.071
201803 3.133 105.290 4.015
201806 0.972 106.317 1.234
201809 0.134 106.507 0.170
201812 0.920 105.998 1.171
201903 0.022 107.251 0.028
201906 0.190 108.070 0.237
201909 0.363 108.329 0.452
201912 0.287 108.420 0.357
202003 0.430 108.902 0.533
202006 0.395 108.767 0.490
202009 2.160 109.815 2.654
202012 0.471 109.897 0.578
202103 0.379 111.754 0.458
202106 0.430 114.631 0.506
202109 0.614 115.734 0.716
202112 7.248 117.630 8.314
202203 0.470 121.301 0.523
202206 0.716 125.017 0.773
202209 0.619 125.227 0.667
202212 0.683 125.222 0.736
202303 0.411 127.348 0.435
202306 0.424 128.729 0.444
202309 0.616 129.860 0.640
202312 0.463 129.419 0.483
202403 0.314 131.776 0.322
202406 0.409 132.554 0.416
202409 0.429 133.029 0.435
202412 0.398 133.157 0.403
202503 1.601 134.927 1.601

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenxbio  (STU:RB0) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Regenxbio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Regenxbio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio Business Description

Industry
Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Regenxbio Headlines

No Headlines